Genomic and Transcriptomic Characterization Reveals B-cell Hyperactivation and Immune Evasion in Hepatitis B Virus-Associated Diffuse Large B-cell Lymphoma.
Wei Qin,Nan Wang,Qing Shi,Rui Sun,Zhong Zheng,Di Fu,Lei Dong,Chen Li,Yifang Zhang,Pengpeng Xu,Shu Cheng,Ying Qian,Yan Feng,Li Wang,Weili Zhao
DOI: https://doi.org/10.1002/ctm2.1293
IF: 8.554
2023-01-01
Clinical and Translational Medicine
Abstract:Dear Editor, Hepatitis B virus (HBV) is an oncogenic virus and a major risk factor for developing hepatocellular carcinoma.1 Growing evidence also suggests that HBV infection is linked to an increased incidence of diffuse large B-cell lymphoma (DLBCL).1 Among 1925 newly diagnosed DLBCL patients (Figure S1), we revealed that DLBCLs with current HBV infection (HBV-surface-antigen [HBsAg]+), instead of those with previous HBV infection (HBsAg- and antibodies against HBV-core-antigen+), correlated with high-risk clinical features (Table S1), as previously reported.2, 3 The prognostic impact of HBV infection in DLBCL remained controversial in the rituximab era,2, 3 largely due to the relatively small sample size of patients receiving rituximab-containing treatment. Here, among 1490 patients with R-CHOP treatment, we observed that the progression-free survival (PFS) and overall survival (OS) of DLBCLs with current HBV infection were significantly worse than those of non-HBV infection (Figure 1A,B). Moreover, current HBV infection independently predicted adverse PFS and OS when other prognostic variables were adjusted (Figure S2). More elderly patients were observed in the previous HBV infection group, probably due to the universal infant HBV vaccination in China since 2002. HBV indirectly promotes DLBCL tumorigenesis by inducing B-cell hyperactivation.2 Accordingly, in DLBCLs of current HBV infection, transcriptional factors for germinal center (GC) initiation and maintenance4 were upregulated, while transcriptional factor for B-cell differentiation was downregulated, as compared to those of non-HBV infection (Figure 1C). Besides, B-cell surface markers for B-cell development5 were significantly higher in DLBCLs of current HBV infection than in non-HBV infection (Figure 1D). Moreover, DLBCLs of current HBV infection presented upregulated B-cell-related signaling pathways as revealed by single sample Gene Set Enrichment Analysis (GSEA) (Figure 1E, Table S2), and increased major histocompatibility complex class II molecules (Figure S3A, Table S3), which play an essential role in B cell-T cell co-stimulation.4 However, no significant difference was detected between previous HBV infection and non-HBV infection. Upon B-cell activation, B cells enter into the GC to generate high-affinity antibodies through activation-induced cytidine deaminase (AID).6 In pathological conditions, enhanced AID activity induces aberrant generation of genetic mutations and chromosomal translocations.6 Indeed, DLBCLs with current HBV infection exhibited significantly increased BCL6 translocation by fluorescence in situ hybridization (Figure 1F), as well as increased gene mutations, including BTG2, FAS, CD70, TNFRSF14, PTPN6, STAT3, EBF1, and NOTCH1 (Figure 1G). However, no significant difference in chromosomal translocations or gene mutations was detected between previous and non-HBV infection. Moreover, no significant difference of the genetic subtypes (Other, BN2, EZB, MCD, A53, N1, ST2, or genetically composite) was observed among three groups (Figure S3B, Table S4). Together, HBV virus may increase genomic alterations through B-cell hyperactivation under persistent HBV antigen stimulation, contributing to DLBCL development. Based on the similar clinical and molecular patterns, patients with previous and non-HBV infection were grouped as non-current HBV infection. GSEA revealed that current HBV infection was significantly associated with enriched signaling pathways involving B-cell activation and immune regulation (Figure 2A), with CD70 having the highest fold change among the significantly overexpressed genes in current HBV infection group (Figure 2B). By immunohistochemistry, DLBCLs with current HBV infection showed aberrant higher CD70 expression on B-lymphocytes (Figure 2C), indicating association between B-cell activation and CD70 expression. By RNA sequencing, enrichment of B-cell activation positively correlated with CD70 expression (Figure 2D). To confirm the role of B-cell activation on CD70 upregulation, we cultured OCI-LY10 and SU-DHL4 cells with anti-IgG, and observed significantly increased CD70 expression in both cell lines induced by anti-IgG (Figure 2E). T cells play essential roles in chronic HBV infection. As revealed by tumor immunophenotyping, DLBCLs with current HBV infection exhibited significantly increased recruiting activity of regulatory T (Treg) cells (Figure 3A). Treg cells have been recognized to promote immune evasion by controlling the immune activity of T cells.7 Indeed, as compared to the Treg-low group according to the median recruiting score of Treg cells, the Treg-high group showed significantly downregulated signaling pathways related to T-cell immune response (Figure S3C). Treg cell increase in patients with current HBV infection was further confirmed by immunohistochemistry (Figure 3B) and multi-color flow cytometry (Figure 3C, Figure S3D). CD27-CD70 interaction induces critical survival factors for Treg cells, thereby promoting Treg cell differentiation and inhibiting Treg cell apoptosis.8 Consistently, elevated CD70 expression (CD70-high group based on the median CD70 level) was significantly related to higher recruiting activity of Treg cells (Figure S3E). Additionally, key chemokines and chemokine receptors involved in Treg recruitment activity were significantly upregulated in CD70-high group, as compared to CD70-low group (Figure S3F). With ectopic expression of CD70 through transfecting with CD70-vector in OCI-LY10 and SU-DHL4 cells (Figure 3D,E), CD70 facilitated lymphoma cell proliferation in both cell lines (Figure 3F), in consistent with previous study that CD70 may induce a growth advantage of B cells.9 Under co-culture system with peripheral blood mononuclear cells, CD70 overexpression on OCI-LY10 and SU-DHL4 cells significantly promoted Treg cell increasing (Figure 3G) and tumor cell proliferation as well (Figure 3H). Therefore, HBV infection may increase Treg cells via CD70, thereby inducing tumor escape from immune surveillance and subsequent DLBCL progression. Lenalidomide is an effective immunomodulatory agent in treating DLBCL and exerts anti-tumor activity through targeting Treg cells.10 Upon lenalidomide treatment, both co-culture systems elicited significantly decreased Treg cells (Figure 4A) and tumor cells (Figure 4B). We next treated 52 relapsed/refractory patients with rituximab, ifosfamide, carboplatin, and etoposide (R-ICE), and observed DLBCLs with current HBV infection displayed significantly shorter PFS and OS than those of non-current HBV infection (Figure 4C). When relapsed/refractory patients received lenalidomide plus R-ICE, lenalidomide significantly improved the PFS and OS of DLBCLs with current HBV infection (Figure 4D). Of note, Treg cells remained unchanged upon R-ICE treatment (Figure 4E), but were significantly decreased upon lenalidomide plus R-ICE treatment in patients with current HBV infection (Figure 4F). In conclusion, DLBCLs with current HBV infection may refer as a specific entity with aggressive disease course and resistance to immunochemotherapy. Targeting tumor microenvironment could be promising approaches for mechanism-based treatment on virus-related B-cell malignancies. We appreciate the effort of the physicians for enrolling patients, the bioinformatic support of Computational Biology Group from Network & Information Center at Shanghai Jiao Tong University, and thank all the patients involved for allowing us to analyze their clinical data. Graphical Abstract was created with BioRender. This study was supported by the National Natural Science Foundation of China (82130004, 81830007, and 82070204), Shanghai Municipal Education Commission Gaofeng Clinical Medicine (20152206 and 20152208), Multicenter Clinical Research Project by Shanghai Jiao Tong University School of Medicine (DLY201601), Clinical Research Plan of Shanghai Hospital Development Center (SHDC2020CR1032B), Chang Jiang Scholars Program, Samuel Waxman Cancer Research Foundation, and the Foundation of National Facility for Translational Medicine (Shanghai, TMSK-2020-115). The authors declare that they have no conflict of interest. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.